FDA Approves Lytenava: First Official Eye-Only Version of Bevacizumab for Wet AMD
Purpose-built for the eye, it ends years of off-label repackaging.
/ 5 items
#OTLK↓
Outlook Therapeutics Resubmits FDA Application for LYTENAVA – Wet AMD Treatment One Step Closer to Approval
Outlook resubmits FDA application for LYTENAVA eye injection for wet AMD. Decision expected in 60 days.
FDA Overturns Rejection: Outlook Therapeutics to Resubmit Lytenava in June
Outlook Therapeutics jumps after FDA appeal win; plans June 2026 resubmission of Lytenava, with possible approval in summer.
Outlook Therapeutics Stock Plunges After FDA Rejects Eye Drug for Third Time
Outlook Therapeutics (OTLK) shares crashed 63% after FDA rejected its wet AMD treatment ONS-5010/Lytenava again, requesting more efficacy evidence without specifying requirements.
Outlook ONS-5010 BLA Accepted; FDA Target Date Dec 31, 2025
Outlook Therapeutics' potential new treatment, ONS-5010 (LYTENAVA), is under FDA review following a successful BLA resubmission. The decision is expected by December 31, 2025.